TY - JOUR
T1 - High-dose inhaled terbutaline increases muscle strength and enhances maximal sprint performance in trained men
AU - Hostrup, Morten
AU - Kalsen, Anders
AU - Bangsbo, Jens
AU - Hemmersbach, Peter
AU - Karlsson, Sebastian
AU - Backer, Vibeke
N1 - CURIS 2014 NEXS 241
PY - 2014/12
Y1 - 2014/12
N2 - Purpose: The purpose of the present study was to investigate the effect of high-dose inhaled terbutaline on muscle strength, maximal sprinting, and time-trial performance in trained men. Methods: Nine non-asthmatic males with a (Formula presented.) of 58.9 ± 3.1 ml min−1 kg−1 (mean ± SEM) participated in a double-blinded randomized crossover study. After administration of inhaled terbutaline (30 × 0.5 mg) or placebo, subjects’ maximal voluntary isometric contraction (MVC) of m.quadriceps was measured. After MVC, subjects performed a 30-s Wingate test. Sixty minutes following the Wingate test, subjects exercised for 10 min at 80 % of (Formula presented.) and completed a 100-kcal time trial. Aerobic contribution was determined during the Wingate test by indirect calorimetry. Furthermore, plasma terbutaline, lactate, glucose, and K+ were measured. Results: Inhalation of 15 mg terbutaline resulted in systemic concentrations of terbutaline of 23.6 ± 1.1 ng ml−1 30 min after administration, and elevated plasma lactate (P = 0.001) and glucose (P = 0.007). MVC was higher for terbutaline than placebo (738 ± 64 vs. 681 ± 68 N) (P = 0.007). In addition, Wingate peak power and mean power were 2.2 ± 0.8 (P = 0.019) and 3.3 ± 1.0 % (P = 0.009) higher for terbutaline than placebo. Net accumulation of plasma lactate was higher (P = 0.003) for terbutaline than placebo during the Wingate test, whereas (Formula presented.) above baseline was unchanged by terbutaline (P = 0.882). Time-trial performance was not different between treatments (P = 0.236). Conclusion: High-dose inhaled terbutaline elicits a systemic response that enhances muscle strength and sprint performance. High-dose terbutaline should therefore continue to be restricted in competitive sport.
AB - Purpose: The purpose of the present study was to investigate the effect of high-dose inhaled terbutaline on muscle strength, maximal sprinting, and time-trial performance in trained men. Methods: Nine non-asthmatic males with a (Formula presented.) of 58.9 ± 3.1 ml min−1 kg−1 (mean ± SEM) participated in a double-blinded randomized crossover study. After administration of inhaled terbutaline (30 × 0.5 mg) or placebo, subjects’ maximal voluntary isometric contraction (MVC) of m.quadriceps was measured. After MVC, subjects performed a 30-s Wingate test. Sixty minutes following the Wingate test, subjects exercised for 10 min at 80 % of (Formula presented.) and completed a 100-kcal time trial. Aerobic contribution was determined during the Wingate test by indirect calorimetry. Furthermore, plasma terbutaline, lactate, glucose, and K+ were measured. Results: Inhalation of 15 mg terbutaline resulted in systemic concentrations of terbutaline of 23.6 ± 1.1 ng ml−1 30 min after administration, and elevated plasma lactate (P = 0.001) and glucose (P = 0.007). MVC was higher for terbutaline than placebo (738 ± 64 vs. 681 ± 68 N) (P = 0.007). In addition, Wingate peak power and mean power were 2.2 ± 0.8 (P = 0.019) and 3.3 ± 1.0 % (P = 0.009) higher for terbutaline than placebo. Net accumulation of plasma lactate was higher (P = 0.003) for terbutaline than placebo during the Wingate test, whereas (Formula presented.) above baseline was unchanged by terbutaline (P = 0.882). Time-trial performance was not different between treatments (P = 0.236). Conclusion: High-dose inhaled terbutaline elicits a systemic response that enhances muscle strength and sprint performance. High-dose terbutaline should therefore continue to be restricted in competitive sport.
U2 - 10.1007/s00421-014-2970-2
DO - 10.1007/s00421-014-2970-2
M3 - Journal article
C2 - 25113095
SN - 8750-7587
VL - 114
SP - 2499
EP - 2508
JO - Journal of Applied Physiology
JF - Journal of Applied Physiology
IS - 12
ER -